Protein kinase C--a novel target for rational anti-cancer drug design?
Gescher
A
A
Pharmaceutical Sciences Institute, Aston University, Birmingham, UK.
Dale
I L
IL
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology; D002455:Cell Division / Q000187:drug effects / Q000502:physiology; D015195:Drug Design; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D004789:Enzyme Activation / Q000187:drug effects; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000201:enzymology; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000502:physiology*; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; D011493:Protein Kinase C